I think that is a reasonable estimate especially if you are counting Car-T. There are so many doors that open with the BLA for Lenz. Company has mentioned National Stockpile and Non-Covid ARDS in previous Investor Calls. We are literally Weeks to a Month away from a Phase III EUA that will lead to a BLA in early 2021 for Lenzilumab and becoming the S.O.C. in Covid, and opening doors to so many other applications. There are really big things on tap here.
Market Data 
Markets 
AI
